Haisco Pharmaceutical's Attributable Profit Expands Fivefold in H1

MT Newswires Live

Aug 27

Haisco Pharmaceutical's (SHE:002653) attributable profit ballooned 427%, or about 5.3 times, to 851.2 million yuan in the first half from 161.5 million yuan, after adjustments, in the year-ago period, according to a Thursday filing with the Shanghai/Shenzhen Stock Exchange.

Earnings per share at the drug company expanded to 0.7601 yuan from 0.1442 yuan in the prior-year period.

Operating revenue grew 55% year over year to 3.10 billion yuan from 2.00 billion yuan.

Directors declared a dividend of 5.26 yuan per 10 shares, or 0.526 yuan per share.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2662720918"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2662720918\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2662720918?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-27 13:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2662720918","market":"nz","top_or_hot":-1,"title":"Haisco Pharmaceutical's Attributable Profit Expands Fivefold in H1","media":"MT Newswires Live","content":"<html><body><p> Haisco Pharmaceutical's (SHE:002653) attributable profit ballooned 427%, or about 5.3 times, to 851.2 million yuan in the first half from 161.5 million yuan, after adjustments, in the year-ago period, according to a Thursday filing with the Shanghai/Shenzhen Stock Exchange.</p><p>Earnings per share at the drug company expanded to 0.7601 yuan from 0.1442 yuan in the prior-year period.</p><p>Operating revenue grew 55% year over year to 3.10 billion yuan from 2.00 billion yuan.</p><p>Directors declared a dividend of 5.26 yuan per 10 shares, or 0.526 yuan per share.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Haisco Pharmaceutical's Attributable Profit Expands Fivefold in H1</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHaisco Pharmaceutical's Attributable Profit Expands Fivefold in H1\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-27 13:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Haisco Pharmaceutical's (SHE:002653) attributable profit ballooned 427%, or about 5.3 times, to 851.2 million yuan in the first half from 161.5 million yuan, after adjustments, in the year-ago period, according to a Thursday filing with the Shanghai/Shenzhen Stock Exchange.</p><p>Earnings per share at the drug company expanded to 0.7601 yuan from 0.1442 yuan in the prior-year period.</p><p>Operating revenue grew 55% year over year to 3.10 billion yuan from 2.00 billion yuan.</p><p>Directors declared a dividend of 5.26 yuan per 10 shares, or 0.526 yuan per share.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2662720918","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2662720918","pubTimestamp":1787806840,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Haisco Pharmaceutical's  attributable profit ballooned 427%, or about 5.3 times, to 851.2 million yuan in the first half from 161.5 million yuan, after adjustments, in the year-ago period, according to a Thursday filing with the Shanghai/Shenzhen Stock Exchange.Earnings per share at the drug company expanded to 0.7601 yuan from 0.1442 yuan in the prior-year period.Operating revenue grew 55% year over year to 3.10 billion yuan from 2.00 billion yuan.Directors declared a dividend of 5.26 yuan per 10 shares, or 0.526 yuan per share.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0188":"融资融券","002653":"海思科","BK0033":"西藏振兴","FCA":"First Trust China AlphaDEX Fund","BK0239":"医药制造","BK0028":"国家队","BK0077":"质押式回购"},"translate_title":"海斯科制药上半年应占利润增长五倍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002653":0.9,"FCA":0.9},"content_text":"Haisco Pharmaceutical's (SHE:002653) attributable profit ballooned 427%, or about 5.3 times, to 851.2 million yuan in the first half from 161.5 million yuan, after adjustments, in the year-ago period, according to a Thursday filing with the Shanghai/Shenzhen Stock Exchange.Earnings per share at the drug company expanded to 0.7601 yuan from 0.1442 yuan in the prior-year period.Operating revenue grew 55% year over year to 3.10 billion yuan from 2.00 billion yuan.Directors declared a dividend of 5.26 yuan per 10 shares, or 0.526 yuan per share.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}